Citable filing context
ILMN's research view summarizes recent SEC filing context, starting with debt_offering from Aug 17, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 17, 2026 | debt_offering | Illumina completed a $300 million public offering of 4.950% notes due 2029. |
| Aug 13, 2026 | debt_offering | Illumina entered into a new $1 billion five-year senior unsecured revolving credit facility maturing in 2031. |
| Aug 12, 2026 | debt_offering | Illumina entered an agreement to issue $300 million in 4.950% notes due 2029. |
| Jul 30, 2026 | Guidance: non_gaap_diluted_eps | 5.30 to 5.40 |
| Jul 30, 2026 | Guidance: non_gaap_operating_margin | 23.40 to 23.60 |
| Jul 30, 2026 | Guidance: row_organic_revenue_growth | 5.00 to not reported |
| Jul 31, 2026 | mda_quarterly | Illumina reported a 7% revenue increase to $2.251 billion for the first half of 2026, driven by strong demand for NovaSeq X instruments and associated consumables. Operating margin improved to 20.2% from 18.0% in the prior-year period. The company’s strategic expansion into proteomics was bolstered by the January 2026 acquisition of SomaLogic, which contributed to service revenue growth but exerted downward pressure on gross margins. Despite top-line growth, profitability remains constrained by several headwinds. Gross margin, while benefiting from the absence of a prior-year intangible asset impairment, was negatively impacted by higher tariff costs, increased freight and energy expenses linked to Middle East instability, rising memory chip costs, and a sales mix shift toward lower-margin instruments. Geopolitical and macroeconomic challenges persist, notably the company’s inclusion on China’s "unreliable entities list," which contributed to a $27 million year-to-date revenue decline in the Greater China region. Liquidity remains robust with $1.04 billion in cash and short-term investments. The company continues to prioritize capital allocation through share repurchases, with $1.779 billion in remaining authorization across its 2024 and 2026 programs. Management expects ongoing volatility from supply-chain disruptions, inflation, and reduced U.S. NIH funding to influence future operational results. |
| May 4, 2026 | mda_quarterly | Illumina reported Q1 2026 revenue of $1,091 million, a 5% increase driven primarily by strong demand for NovaSeq X instruments and consumables. Operating margins expanded to 19.2% from 15.8% in the prior year, while gross margin rose slightly to 66.1%. A key strategic expansion was the January 2026 acquisition of SomaLogic for $460 million, which advances the company's multiomics strategy by integrating high-throughput proteomics technology. Despite these gains, the company faces significant geopolitical and macroeconomic headwinds. Inclusion on China's unreliable entities list resulted in a $20 million revenue decrease in the Greater China region. Additionally, IEEPA-related tariffs on imports from Singapore have increased costs, though Illumina is currently seeking administrative refunds. Other pressing risks include rising memory chip costs, increased freight and energy expenses stemming from instability in the Middle East, and reductions in U.S. government funding for the NIH. Liquidity remains robust with $1,089 million in cash and cash equivalents, supported by $104 million in proceeds from the sale of GRAIL investments. To return capital to shareholders, the Board authorized a new $1.5 billion share repurchase program in April 2026. |
Source: SEC EDGAR filing text and events; period Aug 17, 2026; filed Aug 17, 2026.
ILMN company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.